Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Acro Biomedical Co ( (ACBM) ) has provided an announcement.
On August 14, 2025, Acro Biomedical Co. underwent a significant leadership change as Pao-Chi Chu resigned from his roles as director, chairman, and chief executive officer, with no disagreements cited as the cause. The board appointed Yu-Ting Su as the new director, chairman, and CEO on the same day. Ms. Su brings experience from her previous roles as vice president in the cell banking division at BioSpring Co., Ltd. and in new drug development at BioSeed Co., Ltd., indicating a strategic shift towards leveraging her expertise in nucleic acid manufacturing and biotechnology.
More about Acro Biomedical Co
Technical Sentiment Signal: Sell
Current Market Cap: $42.03K
For an in-depth examination of ACBM stock, go to TipRanks’ Overview page.